OBJECTIVE: To investgate the effect of Xuebijing Injection on immune regulation in patients with systemic inflammatory response syndrome (SIRS). METHODS:56 SIRS patients admitted to the ICU of Guizhou Provincial Hospital from January 2013 to December 2013 were included in this study. The patients were randomly divided into a control (C) and a treatment (T) group. Patients in C group received routine treatment; while patients in T group received additional Xuebijing Injection 50 mL Bid. The following indicators were recorded and compared between the two groups before and 4 and 7 days after treatments: CD4+, CD8+, CD4+/CD8+, monocytes CD14+/human leukocyte antigen-DR (HLA-DR), score of acute physiology and chronic health evaluation II (APACHE II), heart rate, white blood cells, body temperature, respiration rate, and MODS (7 d after treatment only). RESULTS: No differences were found between the two groups before treatments (P > 0.05). T Group had higher levels of CD4+, CD8, CD4+/CD8+ and monocytes CD14+/HLA-DR than C group at 4 and 7 d after treatments (P < 0.05). T group also had higher levels of improvement in vital indicators compared with C group (P < 0.05). No significant difference in incidence of multiple organ dysfunction syndrome (MODS) was found between the two groups (P > 0.05). CONCLUSION:Xuebijing Injection can regulate immune function of patients with SIRS.
RCT Entities:
OBJECTIVE: To investgate the effect of Xuebijing Injection on immune regulation in patients with systemic inflammatory response syndrome (SIRS). METHODS: 56 SIRS patients admitted to the ICU of Guizhou Provincial Hospital from January 2013 to December 2013 were included in this study. The patients were randomly divided into a control (C) and a treatment (T) group. Patients in C group received routine treatment; while patients in T group received additional Xuebijing Injection 50 mL Bid. The following indicators were recorded and compared between the two groups before and 4 and 7 days after treatments: CD4+, CD8+, CD4+/CD8+, monocytes CD14+/human leukocyte antigen-DR (HLA-DR), score of acute physiology and chronic health evaluation II (APACHE II), heart rate, white blood cells, body temperature, respiration rate, and MODS (7 d after treatment only). RESULTS: No differences were found between the two groups before treatments (P > 0.05). T Group had higher levels of CD4+, CD8, CD4+/CD8+ and monocytes CD14+/HLA-DR than C group at 4 and 7 d after treatments (P < 0.05). T group also had higher levels of improvement in vital indicators compared with C group (P < 0.05). No significant difference in incidence of multiple organ dysfunction syndrome (MODS) was found between the two groups (P > 0.05). CONCLUSION: Xuebijing Injection can regulate immune function of patients with SIRS.